



ScienceDirect

Contents lists available at sciencedirect.com
Journal homepage: www.elsevier.com/locate/jval

HEOR in the Broader Context of HTA/CER

“Time Traveling Is Just Too Dangerous” but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier



Fernando Alarid-Escudero, PhD,^{1,*} Eva A. Enns, PhD,² Karen M. Kuntz, ScD,² Tzeyu L. Michaud, PhD,³ Hawre Jalal, MD, PhD⁴

¹Drug Policy Program, Center for Research and Teaching in Economics (CIDE)-CONACyT, Aguascalientes, Mexico; ²Division of Health Policy and Management, University of Minnesota School of Public Health, Minneapolis, MN, USA; ³Department of Health Promotion and Center for Reducing Health Disparities, College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA; ⁴Department of Health Policy and Management, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.

ABSTRACT

Background: Cost-effectiveness acceptability curves (CEACs) and the cost-effectiveness acceptability frontier (CEAF) are the recommended graphical representations of uncertainty in a cost-effectiveness analysis (CEA). Nevertheless, many limitations of CEACs and the CEAF have been recognized by others. Expected loss curves (ELCs) overcome these limitations by displaying the expected foregone benefits of choosing one strategy over others, the optimal strategy in expectation, and the value of potential future research all in a single figure.

Objectives: To revisit ELCs, illustrate their benefits using a case study, and promote their adoption by providing open-source code.

Methods: We used a probabilistic sensitivity analysis of a CEA comparing 6 cerebrospinal fluid biomarker test-and-treat strategies in patients with mild cognitive impairment. We showed how to calculate ELCs for a set of decision alternatives. We used the probabilistic sensitivity analysis of the case study to illustrate the limitations of currently recommended methods for communicating uncertainty and then demonstrated how ELCs can address these issues.

Results: ELCs combine the probability that each strategy is not cost-effective on the basis of current information and the expected foregone benefits resulting from choosing that strategy (ie, how much is lost if we recommended a strategy with a higher expected loss). ELCs display how the optimal strategy switches across willingness-to-pay thresholds and enables comparison between different strategies in terms of the expected loss.

Conclusions: ELCs provide a more comprehensive representation of uncertainty and overcome current limitations of CEACs and the CEAF. Communication of uncertainty in CEA would benefit from greater adoption of ELCs as a complementary method to CEACs, the CEAF, and the expected value of perfect information.

Keywords: cost-effectiveness analysis, expected losses, probabilistic sensitivity analysis, uncertainty analysis, value of information analysis.

VALUE HEALTH. 2019; 22(5):611–618

Introduction

Cost-effectiveness analyses (CEAs) are generally conducted with some degree of parameter uncertainty. This parameter uncertainty is often accounted for in a probabilistic sensitivity analysis (PSA), which translates parameter uncertainty into decision uncertainty, namely, the probability that a given strategy is cost-effective.¹ In a typical CEA, the decision maker is assumed to be risk-neutral, with the optimal decision defined as the strategy maximizing the expected net benefit regardless of the

level of decision uncertainty. Therefore, the primary purpose of the quantification of decision uncertainty is simply to provide confidence in the chosen strategy.² Nevertheless, parameter uncertainty plays a crucial role in determining the potential consequences of a decision, which are used to quantify the value of potential future research.^{1–3}

PSA has become widely adopted and is now required by many journals, guidelines, and funding agencies^{1,4–9} and is even considered “essential to high-quality cost-effectiveness analysis (CEA).”⁴ In a typical analysis, the PSA is used to construct a

* Address correspondence to: Fernando Alarid-Escudero, PhD, Drug Policy Program, Center for Research and Teaching in Economics (CIDE)-CONACyT, Circuito Tecnopolio Norte 117, Col. Tecnopolio Pocitos II, Aguascalientes 20313, Mexico. Email: fernando.alarid@cide.edu

1098-3015/\$36.00 - see front matter Copyright © 2019, ISPOR—The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. <https://doi.org/10.1016/j.jval.2019.02.008>

cost-effectiveness acceptability curve (CEAC) for each strategy and the cost-effectiveness acceptability frontier (CEAF). A CEAC illustrates the proportion of PSA samples in which a given strategy is cost-effective (ie, with the highest net benefit) as a function of the willingness-to-pay (WTP) threshold.^{10–13} This proportion is interpreted as the probability that a strategy is cost-effective, given the level of parameter uncertainty present in the analysis. The CEAC plot displays the CEAC of each of the strategies and is used for comparison of multiple strategies in the presence of uncertainty.¹¹ The CEAF can be overlaid on top of the CEAC plot, showing the probability that the optimal strategy (ie, the strategy with the highest expected net benefit) is cost-effective as a function of WTP.^{11,14} Notably, the CEAF in combination with the CEAC sometimes reveals that the best strategy in expectation is not always the strategy that is most likely to be cost-effective at a given WTP³ (see Appendix A in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2019.02.008> for a more detailed description on the differences between the strategy with the highest probability of being cost-effective and the most cost-effective strategy). The inclusion of the CEAF alongside the CEAC is important, because the strategy that is most likely to be cost-effective should not be conflated with the strategy that is optimal in expectation in the decision-making process.¹

Despite their widespread use,¹⁵ it is unclear whether CEACs and the CEAF have much influence on policy recommendations. Ultimately, a risk-neutral decision maker will choose the strategy with the highest net benefit in expectation, regardless of the level of uncertainty about whether this strategy is cost-effective. In situations in which the CEACs and the CEAF reveal that the optimal strategy has a qualitatively low probability of being cost-effective and is not the strategy that is most likely to be cost-effective at a decision maker's WTP, the decision maker may feel a certain level of discomfort in their decision. Nevertheless, the extent to which their level of decision uncertainty is truly a cause of concern is not among the information provided by the CEAC/CEAF plot.

In particular, the CEAC/CEAF plot does not capture the magnitude of the net benefit lost in the proportion of PSA samples when the chosen strategy is not cost-effective³; yet it is the expected loss in net benefit that is truly the concern of the decision maker because this represents the foregone benefits resulting from having chosen a given strategy. For example, consider a situation in which the optimal strategy in expectation is cost-effective for only 30% of PSA samples at a given WTP. If among the remaining 70% of PSA samples the difference in net benefit between the optimal strategy and the strategy that achieves the maximal net benefit for that sample is generally small, this may not be of great concern to a decision maker. Nevertheless, if there are even just a few PSA samples for which the optimal strategy results in a large amount of foregone benefits, the low level of decision uncertainty should be of greater concern. Furthermore, the CEACs and the CEAF do not communicate the ordinal information in the ranking of the strategies by their expected benefits, which could be useful when implementing the optimal strategy is not feasible.

Value of information (VOI) is the quantification of the value of potential future research to better inform a decision in the presence of parameter uncertainty. In general, VOI measures the foregone benefits from choosing a strategy given imperfect information.^{16,17} The most commonly used VOI metric is the expected value of perfect information (EVPI), which represents the value of eliminating parameter uncertainty of CEA.^{18–20} Formally, EVPI is the difference between the expected net benefit given current information and the expected net benefit given perfect

information (ie, no uncertainty in model parameters). EVPI also represents the maximum value provided by potential future research¹⁷ that could help inform decisions on research prioritization, which is something not provided by CEACs or the CEAF.

These limitations of CEACs and the CEAF in communicating the extent to which decision uncertainty *matters* have been recognized by others²¹ and can be addressed by using expected loss curves (ELCs). ELCs have been proposed by others^{22–25} and present a quantification of the consequences of choosing a suboptimal strategy in terms of expected foregone benefits, plotted as a function of WTP. In addition to showing the extent to which decision uncertainty results in a loss in benefits, ELCs also display the optimal strategy for a risk-neutral decision maker (like the CEAF), the value of eliminating the current level of decision uncertainty through additional research (like the EVPI),²² and the ranking of strategies in terms of expected losses. That is, the use of ELCs is a practical way to convey information about what is optimal given current information, the consequences of decision uncertainty, and the value of potential future research in a single graphical representation. ELCs arguably provide a more useful representation of uncertainty than does the information contained in CEACs, CEAF, and EVPI alone; yet, the use of ELCs has been limited in the field of medical decision making to a handful of conceptual and methodological articles.

The aim of this article was to revisit ELCs and promote their use as a complementary approach to CEACs, CEAF, and EVPI to represent the results of uncertainty analysis in CEA. We start with the mathematical definitions of the CEAC, CEAF, and ELCs and provide open-source code to compute these methods from a typical PSA data set. We then illustrate the issues with CEACs and the CEAF for communicating results of uncertainty analysis in CEA using a published study of cerebrospinal fluid (CSF) biomarker testing in patients with mild cognitive impairment (MCI) and show how ELCs can address these issues. We show that ELCs highlight not only the optimal strategy in the presence of parameter uncertainty but also the quantification of the value of potential future research to address this uncertainty. We conclude by arguing that ELCs provide additional information to a decision maker not revealed by CEACs and the CEAF.

Methods

To estimate CEACs, the CEAF, and ELCs, we need to compute the net benefit for each strategy. Consider a CEA that compares D strategies in terms of their effectiveness, E , and costs, C . The net benefit of a given strategy is often considered in monetary terms and referred to as net monetary benefit. The net monetary benefit for strategy d , B_d , is defined as $E_d \lambda - C_d$, where E_d and C_d are its effectiveness and costs, respectively, and λ is the WTP for 1 unit of effectiveness.²⁶

The Cost-Effectiveness Acceptability Curves

The probability that strategy d is cost-effective, $Pr(CE)_d$, is computed as follows:

$$Pr(CE)_d = \frac{N_d}{N}, \quad (1)$$

where N_d is the number of simulations in which strategy d has the maximum net benefit and N is the total number of PSA samples. The CEAC plot is the representation of $Pr(CE)_d$ for all strategies being compared in the CEA as a function of WTP.

The Cost-Effectiveness Acceptability Frontier

Let $B_{i,d}$ be the net benefit for the i -th simulation of the PSA data set for a strategy d , and $\bar{B} = [\bar{B}_1 \ \bar{B}_2 \ \dots \ \bar{B}_d \ \dots \ \bar{B}_D]$ be the expected net benefit of all D strategies averaged across all N simulations of a PSA, where the expected net benefit for strategy d , \bar{B}_d , is defined as $\bar{B}_d = \frac{1}{N} \sum_{i=1}^N B_{i,d} \ \forall d \in [1, \dots, D]$. Then, the optimal strategy based on the highest expected net benefit, d_B^* , is defined as follows:

$$d_B^* = \operatorname{argmax}_{d \in [1, 2, \dots, D]} \{\bar{B}_d\}. \quad (2)$$

The CEAF is the representation of the optimal strategy, d_B^* , as a function of WTP.

Definition and Mathematical Notation of Expected Losses

The expected loss is the quantification of the foregone benefits when choosing a suboptimal strategy given current evidence. Formally, the expected loss of strategy d , \bar{L}_d , averaged across all N simulations of a PSA is computed as follows:

$$\bar{L}_d = \frac{1}{N} \sum_{i=1}^N [B_{i,d_i^*} - B_{i,d}], \quad (3)$$

$$\bar{L}_d = \frac{1}{N} \sum_{i=1}^N B_{i,d_i^*} - \frac{1}{N} \sum_{i=1}^N B_{i,d}; \ \forall d \in [1, \dots, D], \quad (4)$$

where $B_{i,d_i^*} = \max_d(B_{i,d})$ is the net benefit of the optimal strategy for the i -th PSA sample, denoted as d_i^* .

For a risk-neutral decision maker, the optimal strategy is the strategy with the highest expected benefit, which is equivalent to the strategy with the lowest expected loss. Furthermore, the expected loss of the optimal strategy equals the EVPI in the decision problem²³ (see Appendix B in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2019.02.008> for a step-by-step derivation of these statements). Thus, once the expected loss is calculated for all D strategies, it is possible to determine both the optimal strategy and the EVPI.

The Expected Loss Curves

ELCs are a representation of the expected loss of all D strategies, $L = [\bar{L}_1 \ \bar{L}_2 \ \dots \ \bar{L}_d \ \dots \ \bar{L}_D]$, as a function of WTP. The ELCs reveal the optimal strategy defined as the strategy with the lowest expected loss at a given WTP. The lower envelope of the ELCs is the expected loss of the optimal strategy and also the EVPI of the decision problem at that WTP. The ELCs also reveal by how much the optimal strategy is better than each of the other alternatives in terms of expected foregone benefits, which could be relevant when determining how resources should be spent.²⁷ Furthermore, ELCs could be used to rank the strategies on the basis of their expected loss, which could be useful in cases in which implementing the optimal strategy is not feasible (eg, a technology not available in a local setting).

The ELCs show the expected loss (y -axis) of all strategies as a function of the WTP threshold (x -axis). If the differences in expected loss among strategies are small, these differences could be visually magnified by log-transforming the y -axis. R code to compute CEACs, the CEAF, ELCs, and EVPI from a typical PSA data set is provided in Appendix C in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2019.02.008>. Readers could also

have access to these methods through the R package **dampack** hosted on GitHub available at <https://github.com/DARTH-git/dampack>.

Case Study: CEA of CSF Biomarker Testing in Patients With MCI

Here we summarize a previously published model for assessing the cost effectiveness of 6 CSF biomarker test-and-treat strategies in patients with MCI. For full model details, see the study of Michaud et al.²⁸ All analyses were conducted in R version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria).²⁹

The CEA of CSF biomarker testing and targeted treatment compared 6 test-and-treat strategies in patients with MCI where the treatment decision was based on patients' risk level (low, intermediate, and high) of progression to Alzheimer disease (AD). The analysis used a Markov model of MCI and AD to project lifetime quality-adjusted life-years (QALYs) and costs for a cohort of 65-year-old patients with MCI from a US societal perspective. The 6 strategies were as follows:

1. *Test and treat low risk*: Test patients with MCI and treat those with a low-risk result until AD conversion; no treatment for high- and intermediate-risk patients until they convert to AD and stop treatment when they progress to the severe stage.
2. *Test and treat low or intermediate risk*: Test patients with MCI and treat those with a low- or intermediate-risk result until AD conversion; no treatment for high-risk patients.
3. *No testing and no MCI treatment*: Treat only when patients with MCI convert to AD and stop treatment when they progress to the severe stage.
4. *Test and treat high risk*: Test patients with MCI and treat only those with a high-risk result until AD conversion; no treatment for low- and intermediate-risk patients until they convert to AD and stop treatment when they progress to the severe stage.
5. *Test and treat high or intermediate risk*: Test patients with MCI and treat those with a high- or intermediate-risk result until AD conversion; no treatment for low-risk patients until they convert to AD and stop treatment when they progress to the severe stage.
6. *No testing and treat all patients with MCI*: Treat all patients with MCI and stop treatment when patients convert to AD.


For patients with MCI who received treatment, the authors assumed they would not be eligible for treatment once they converted to AD and stopped treatment when they progressed to the severe stage of AD. The PSA of the CEA of CSF biomarker testing included uncertainty in parameters describing disease progression, treatment effectiveness and harm, health utilities, and costs of disease, treatment, and CSF biomarker testing. The PSA data set was conducted with 10 000 samples.

Results

Results of the PSA of the Case Study

Figure 1A shows the CEACs and the CEAF generated from the PSA of the CEA of CSF biomarker test-and-treat strategies in patients with MCI. For a WTP threshold lower than \$15 000/QALY, testing and treating patients with MCI at high or intermediate risk has the highest expected net benefit but has a lower probability of being cost-effective compared with some of the other strategies. For WTP thresholds between \$15 000/QALY and \$35 000/QALY, the strategy of no testing and treating all patients with MCI is the strategy with the highest expected net benefit and

Figure 1. (A) CEACs displaying the probability of each strategy being cost-effective across all simulations of the PSA and the CEAF displaying the probability of the optimal strategy (in a gray square) being cost-effective across a range of WTP thresholds. (B) ELCs displaying across a range of WTP thresholds: (1) the expected loss in US dollars (in thousand) for each of the strategies of the CEA of CSF biomarker testing; (2) the optimal strategy inside the gray square, which is the strategy with the lowest expected loss; and (3) the EVPI, which is the expected loss corresponding to the optimal strategy inside the gray square. The scale of the y-axis is logarithmic.



CEA indicates cost-effectiveness analysis; CEAC, cost-effectiveness acceptability curve; CEAF, cost-effectiveness acceptability frontier; CSF, cerebrospinal; ELC, expected loss curve; EVPI, expected value of perfect information; MCI, mild cognitive impairment; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life-year; WTP, willingness to pay.

also the strategy with the highest probability of being cost-effective. The strategy of no testing and no treating patients with MCI has the highest expected net benefit for WTP thresholds greater than or equal to \$37 500/QALY and lower than \$47 500/QALY and is the strategy with the second highest probability of being cost-effective. The strategy of testing and treating patients with MCI at low risk has the highest expected net benefit for WTP thresholds greater than \$45 000/QALY.

Limitations of CEACs and CEAF in the Case Study

As shown earlier in Figure 1A, by combining CEACs and the CEAF it is possible to determine the optimal strategy and its probability of being cost-effective. Nevertheless, this graph neither shows by how much the optimal strategy is better than the rest nor shows what the second- and third-best strategies are in terms of expected net benefit. Furthermore, there could be

Table 1. Probability of being cost-effective and expected loss at different WTP thresholds of the CEA of 6 CSF biomarker test-and-treat strategies in patients with MCI.

Strategy	WTP = \$50 000/QALY		WTP = \$100 000/QALY		WTP = \$150 000/QALY	
	Probability of being cost-effective	Expected loss (\$)	Probability of being cost-effective	Expected loss (\$)	Probability of being cost-effective	Expected loss (\$)
1. Test and treat low risk*	14%	2690	26%	3061	29%	3997
2. Test and treat low or intermediate risk	9%	2767	24%	3354	28%	4506
3. No testing and no MCI treatment	38%	2766	30%	4323	28%	6445
4. Test and treat high risk	0%	5863	0%	15 021	0%	24 744
5. Test and treat high or intermediate risk	0%	5939	0%	15 313	0%	25 253
6. No testing and treat all patients with MCI	39%	4505	20%	11 963	15%	19 986

CEA indicates cost-effectiveness analysis; CSF, cerebrospinal; MCI, mild cognitive impairment; QALY, quality-adjusted life-year; WTP, willingness to pay.

*Optimal strategy at the 3 WTP thresholds of this table given by the lowest expected loss assuming a risk-neutral decision maker.

cases in which the optimal strategy is better than the second best only by a small margin in terms of expected net benefit but their differences in the probability of being cost-effective are high. In addition, to display the value of conducting additional research, an additional graphical representation is required.

ELCs of the Case Study

The previous limitations could be overcome with ELCs in Figure 1B that displays the expected loss of each of the strategies from the PSA of the CEA of CSF biomarker testing. In this figure, it is possible to better observe how the optimal strategy switches across WTP thresholds and by how much the optimal strategy is better compared with the rest of the strategies on the basis of their expected loss. For example, at a WTP threshold of \$50 000/QALY in Table 1 and Figure 1B, the optimal strategy is testing and treating only low-risk patients (strategy 1), which is the third strategy in terms of probability of being cost-effective, with only 14% and an expected loss of \$2690 (Table 1 and Figure 1B). Then, the second-best strategy (from Figure 1B) is the strategy of no testing and no treatment for any patient (strategy 3), with an expected loss of \$2766, which is also the second in terms of probability of being cost-effective with 38% (Table 1). The difference of 24 percentage points in the probability of being cost-effective between these 2 strategies might seem high, but when looking at the difference in expected losses (and also visually in Figure 1B), there is only a \$76 difference (Table 1). This contrast gets magnified when comparing strategy 3 with the third-best strategy (strategy 2), which has 9% chance of being cost-effective with an expected loss of \$2767, where the difference in probability of being cost-effective is 29 percentage points but only \$1 in expected losses (Table 1). In terms of expected losses, strategy 2 is practically indistinguishable from strategy 3, but looks extremely different in the CEAC in Figure 1A. Furthermore, with neither CEACs nor the CEAF it is possible to determine which are the second- and third-best strategies in terms of their expected loss. That is, the relative order on the probability of being cost-effective is not related to the actual ranking based on expected loss. This information may be useful to decision makers in cases in which not all strategies are viable alternatives in their setting.

As mentioned earlier, the lower frontier of the ELCs in Figure 1B is the expected loss of the optimal strategy, which corresponds to the same values on the EVPI graph in Figure 2.²² For example, at a WTP threshold of \$100 000/QALY, testing and treating patients with MCI at low risk is the optimal strategy with an expected loss and per-person EVPI of \$3061, followed by testing and treating patients with MCI at low or intermediate risk with an expected loss of \$3353 (Table 1). In Figure 1B, it is now evident that the kinks on the per-person EVPI graph in Figure 2 correspond to the WTP thresholds at which the optimal strategy switches.


From the ELCs it is also possible to rank the strategies on the basis of their expected loss. To facilitate determining the ranking of the strategies of the case study, we ordered them in Figure 3 on the basis of their expected loss across a range of WTP thresholds. Figure 3 shows the change in the relative ranking of the strategies as the WTP threshold varies, where the first row represents the optimal strategy across WTP thresholds. For example, testing and treating patients with MCI with high or intermediate risk goes from being the highest ranked (ie, optimal) strategy for WTP thresholds lower than \$15 000/QALY to the lowest ranked strategy for WTP thresholds greater than \$30 000/QALY. The opposite behavior is shown by testing and treating patients with MCI with low risk, where this strategy goes from the lowest rank for WTP thresholds lower than or equal to \$30 000/QALY to the highest rank for WTP thresholds greater than \$45 000/QALY.

Discussion

In this article, we revisited ELCs, showed their advantages over currently recommended methods for communicating parameter uncertainty by providing additional information that could be useful for decision making, and illustrated their use on a published CEA of biomarker testing in patients with MCI. We showed that with ELCs it is possible to display not only the expected loss for all the strategies in a CEA but also the optimal strategy and the EVPI all combined in a single graphical representation.

Although the CEAC represents the probability of a strategy being cost-effective alone, the ELC combines the probability that

Figure 2. EVPI per patient in US dollars across a range of WTP thresholds. The scale of the y-axis is logarithmic.



EVPI indicates expected value of perfect information; QALY, quality-adjusted life-year; WTP, willingness to pay.

each strategy is not cost-effective on the basis of current information with gravity of the loss at each PSA sample (ie, how much is lost if we recommended a strategy with a higher loss than the loss of the cost-effective strategy). Information on which strategy is optimal is also displayed by the CEAF, but with ELCs, it is

possible to determine the value of eliminating all parameter uncertainty from the CEA by comparing different strategies in terms of the expected loss.

Using CEACs in isolation for decision making could be misleading, particularly when the differences among strategies in

Figure 3. Ranking of the strategies on the basis of expected loss across a range of WTP thresholds. The top strategy is the optimal strategy with the lowest expected loss, and the bottom strategy is the worst strategy with the highest expected loss.



MCI indicates mild cognitive impairment; QALY, quality-adjusted life-year; WTP, willingness to pay.

the probability of being cost-effective are high when the optimal strategy is better than the second best only by a small margin in terms of expected net benefits. ELCs are a summary statistic that shows how the optimal strategy ranks and compares relative to the rest of the strategies and provides an estimate of the EVPI as a function of WTP. That is, the use of ELCs is a practical approach that conveys both information on what is optimal given current information and value of future research in a single graphical representation and addresses many of the limitations of the current practice of presenting PSA results.

Although the use of ELCs is not widespread, EVPI is increasingly being reported. By complementing EVPI with ELCs, decision makers will be presented not only with the foregone benefits associated with the optimal strategy but also with the foregone benefits of the competing strategies, enabling the ranking of the strategies. Information on how large the expected loss of the other options compares with the optimal strategy and with each other could be useful to decision makers. Thus, we argue for the use of ELCs in addition to EVPI to complement what is presented by CEACs and the CEAF.

The use of expected losses and ELCs to guide decision making in the presence of uncertainty on the basis of current information and to quantify the value of potential further research was proposed more than a decade ago followed by subsequent publications promoting their use.^{22–25} Despite their advantages over more commonly used methods, the use of ELCs in the field has been limited. In this article, we illustrate the benefits of such an existing method and its advantages over CEACs and the CEAF and aim to promote its wide adoption.

A similar approach to expected losses for decision making has been recently proposed by Grimm et al³⁰ in the context of managed entry agreement schemes. In this approach, the authors define the concept of payer strategy and uncertainty burden (P-SUB) as a measure of overall risk in decision making in the presence of uncertainty, which is equivalent to the expected losses described in this article. In the study, the P-SUB was calculated for 1 WTP threshold, whereas ELCs were calculated over a range of WTP thresholds. Both the P-SUB and the ELCs argue for a better representation of results of decision problems in the presence of uncertainty than currently adopted methods.

ELCs do have some limitations in that they represent only the average loss and do not reflect worst-/best-case scenarios. Some decision makers may find large losses concerning, even if they are relatively rare across PSA samples; other decision makers may explicitly wish to minimize the worst-case scenario (ie, the largest loss) rather than in expectation. For these decision makers, ELCs are insufficient because a small number of large losses could be averaged out by a larger number of smaller losses. To overcome this limitation, loss curves could be constructed that reflect a weighted average of both foregone benefits (ie, expected losses) and worse-case scenarios (ie, maximum losses), weighted according to preferences of the decision maker. This, however, is a topic for further research.

A strength of this work is that it makes explicit the advantages of ELCs over CEACs and the CEAF and illustrates these with a published case study. ELCs could be calculated directly from a traditional PSA data set. To even further facilitate their use and increase their adoption, we provide open-source code in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2019.02.008> that can be applied with slight or no modifications to the output of a PSA that could be obtained from currently used software.

Current guidelines recommend the use of CEACs and the CEAF to provide decision makers with enough information to make a decision on the basis of current information and present EVPI

analysis to quantify the value of potential future research over a relevant range of WTP thresholds.^{1,9} Nevertheless, these methods provide only a partial insight into the impact of parameter uncertainty. The use of ELCs is a more comprehensive approach that provides decision makers with all the required information necessary to make decisions on the basis of current information, quantify the value of eliminating parameter uncertainty, determine the value of potential future research to better inform the decision, and provide the ordinal ranking of strategies.

Conclusions

By adopting ELCs as a complementary method to CEACs, the CEAF, and EVPI to report results of uncertainty analysis in CEA, decision makers are presented with the probability that each strategy is cost-effective, the optimal strategy, the foregone benefits of the optimal strategy and the rest of the strategies, a ranking of the strategies, and the value of conducting potential further research. We hope that this contribution can aid in the adoption of ELCs in future CEAs.

Source of Financial Support

Financial support for this study was provided in part by a grant from the National Council of Science and Technology of Mexico and a doctoral dissertation fellowship from the Graduate School of the University of Minnesota as part of F. Alarid-Escudero's doctoral program. E. A. Enns was supported by a grant from the National Institute of Allergy and Infectious Disease of the National Institutes of Health (award number: K25AI118476). K. M. Kuntz and F. Alarid-Escudero were supported by a grant from the National Cancer Institute (grant number: U01-CA-199335) as part of the Cancer Intervention and Surveillance Modeling Network. H. Jalal was supported by a grant from the National Institutes of Health (grant number: KL2 TR0001856). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funding agencies had no role in the design of the study, interpretation of results, or writing of the article. The funding agreement ensured the authors' independence in designing the study, interpreting the data, and writing and publishing the report.

Supplemental Materials

Supplementary data associated with this article can be found in the online version at <https://doi.org/10.1016/j.jval.2019.02.008>.

REFERENCES

1. Sculpher MJ, Basu A, Kuntz KM, Meltzer DO. Reflecting uncertainty in cost-effectiveness analysis. In: Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, eds. *Cost-Effectiveness in Health and Medicine*. 2nd ed. New York, NY: Oxford University Press; 2017:289–318.
2. Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. *Med Decis Making*. 2012;32(5):722–732.
3. Claxton K. Exploring uncertainty in cost-effectiveness analysis. *Pharmacoeconomics*. 2008;26(9):781–798.
4. Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, eds. *Cost-Effectiveness in Health and Medicine*. 2nd ed. New York, NY: Oxford University Press; 2017.
5. ICER's reference case for economic evaluations: principles and rationale. Institute for Clinical and Economic Review. https://icer-review.org/wp-content/uploads/2018/07/ICER_Reference_Case_July-2018.pdf. Accessed August 31, 2018.
6. Guide to the methods of technology appraisal 2013. National Institute for Clinical Excellence. <http://www.nice.org.uk/article/pmg9/resources/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf>. Accessed August 31, 2018.
7. Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. *Health Econ*. 2005;14(4):339–347.

8. Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. *Value Health*. 2012;15(6):835–842.
9. EUnethHTA Joint Action 2, Work Package 7, Subgroup 3, Heintz E, Gerber-Grote A, Ghabri S, et al. Is there a European view on health economic evaluations? Results from a synopsis of methodological guidelines used in the EUnethHTA partner countries. *Pharmacoeconomics*. 2016;34(1):59–76.
10. Van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-ratios alongside a clinical trial. *Health Econ*. 1994;3(5):309–319.
11. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. *Health Econ*. 2001;10(8):779–787.
12. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves—facts, fallacies and frequently asked questions. *Health Econ*. 2004;13(5):405–415.
13. Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. *Br J Psychiatry*. 2005;187(2):106–108.
14. Barton GR, Briggs AH, Fenwick EAL. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfect information (EVPI). *Value Health*. 2008;11(5):886–897.
15. Meckley LM, Greenberg D, Cohen JT, Neumann PJ. The adoption of cost-effectiveness acceptability curves in cost-utility analyses. *Med Decis Making*. 2010;30(3):314–319.
16. Raiffa H, Schlaifer RO. *Applied Statistical Decision Theory*. Cambridge, MA: Harvard Business School; 1961.
17. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. *Health Econ*. 1996;5(6):513–524.
18. Oostenbrink JB, Al MJ, Oppe M, Rutten-van Mölken MPMH. Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research. *Value Health*. 2008;11(7):1070–1080.
19. Felli JC, Hazen GB. Sensitivity analysis and the expected value of perfect information. *Med Decis Making*. 1998;18(1):95–109.
20. Felli JC, Hazen GB. A Bayesian approach to sensitivity analysis. *Health Econ*. 1999;8(3):263–268.
21. Groot Koerkamp B, Hunink MGM, Stijnen T, Hammitt JK, Kuntz KM, Weinstein MC. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. *Med Decis Making*. 2007;27(2):101–111.
22. Eckermann S, Briggs A, Willan AR. Health technology assessment in the cost-disutility plane. *Med Decis Making*. 2008;28(2):172–181.
23. Eckermann S, Karnon J, Willan AR. The value of information: best informing research design and prioritization using current methods. *Pharmacoeconomics*. 2010;28(9):699–709.
24. Eckermann S, Willan AR. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies. *Pharmacoeconomics*. 2011;29(7):563–577.
25. McCaffrey N, Agar M, Harlum J, Karnon J, Currow D, Eckermann S. Better informing decision making with multiple outcomes cost-effectiveness analysis under uncertainty in cost-disutility space. *PLoS One*. 2015;10(3):e0115544.
26. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. *Med Decis Making*. 1998;18(2):S68–S80.
27. Sculpher M, Claxton K, Pearson SD. Developing a value framework: the need to reflect the opportunity costs of funding decisions. *Value Health*. 2017;20(2):234–239.
28. Michaud TL, Kane RL, McCarten JR, Gaugler JE, Nyman JA, Kuntz KM. Using cerebrospinal fluid biomarker testing to target treatment to patients with mild cognitive impairment: a cost-effectiveness analysis. *Pharmacoeconomics Open*. 2018;2(3):309–323.
29. Jalal H, Pechlivanoglou P, Krijkamp E, Alarid-Escudero F, Enns EA, Hunink MGM. An overview of R in health decision sciences. *Med Decis Making*. 2017;37(7):735–746.
30. Grimm SE, Strong M, Brennan A, Wailoo AJ. The HTA risk analysis chart: visualising the need for and potential value of managed entry agreements in health technology assessment. *Pharmacoeconomics*. 2017;35(2):1287–1296.